CTLA-4 Blockade Synergizes Therapeutically With PARP Inhibition in BRCA1-Deficient Ovarian Cancer

Cancer immunology research - United States
doi 10.1158/2326-6066.cir-15-0044
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Decitabine Enhances Lymphocyte Migration and Function and Synergizes With CTLA-4 Blockade in a Murine Ovarian Cancer Model

Cancer immunology research
Cancer ResearchImmunology
2015English

CTLA-4 Blockade Synergizes With Cryoablation to Mediate Tumor Rejection

OncoImmunology
OncologyAllergyImmunology
2012English

CTLA-4 Blockade Boosts the Expansion of Tumor-Reactive CD8+ Tumor-Infiltrating Lymphocytes in Ovarian Cancer

Scientific Reports
Multidisciplinary
2020English

Radiotherapy Enhances Responses of Lung Cancer to CTLA-4 Blockade

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

PARP Inhibitors in Ovarian Cancer

2013English

RING Domain–deficient BRCA1 Promotes PARP Inhibitor and Platinum Resistance

Journal of Clinical Investigation
Medicine
2016English

PARP Inhibition Sensitizes P53-Deficient Breast Cancer Cells to Doxorubicin-Induced Apoptosis

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2005English

PARP Inhibitors for BRCA1/2-mutated and Sporadic Ovarian Cancer: Current Practice and Future Directions

British Journal of Cancer
Cancer ResearchOncology
2016English

PARP Inhibitor Treatment in Ovarian and Breast Cancer

Current Problems in Cancer
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy